Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, PTK2 and EIF3S3, which, respectively, encode focal adhesion kinase and the p40 subunit of the eukaryotic initiation factor 3, were probable targets within the amplification at 8q23-q24 and may be involved in progression of HCC.
|
14578863 |
2003 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, Rab5a is overexpressed in human HCC and contributes to cancer cell proliferation and invasion through regulation of FAK and AKT signaling.
|
26443539 |
2016 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Circ_0015756 knockdown was shown to increase the expression of miR-7, reduce the proliferation, invasion, migration and resistance to apoptosis, and down-regulate the expression of FAK in HCC.
|
31522588 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma.
|
31698037 |
2020 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
It was also shown that the combination of SKI II and U0126 further attenuated the migration of hepatoma HepG2 cells via FAK/MLC-2 signaling pathway.
|
23545258 |
2013 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present data suggest that PTK2 may be a novel prognostic biomarker for HCC recurrence, and a therapeutic target for HCC treatment.
|
30849480 |
2019 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We also found that the phosphorylation levels of FAK in both of the hepatoma cell lines were higher than that in L02 hepatic cells.
|
15532706 |
2004 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BI-3663 (cereblon-based) degrades PTK2 with a median DC<sub>50</sub> of 30 nM to >80% across a panel of 11 HCC cell lines.
|
30739444 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, miR-151 can function synergistically with FAK to enhance HCC cell motility and spreading.
|
20305651 |
2010 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
|
30292831 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Additionally, high expression of both cPLA2α and p-FAK predicted the worst prognoses for HCC patients.
|
31516757 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
DBH-AS1 facilitated the development of HCC via miR-138/FAK/Src/ERK pathway, establishing the molecular basis of DBH-AS1 in clinical application for HCC.
|
30142544 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data demonstrate a novel function of LOXL4 in tumor metastasis mediated by exosomes through regulation of the FAK/Src pathway and angiogenesis in HCC.
|
30704479 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CD31 regulates metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway.
|
29746931 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression levels of beta-catenin, cyclin D1, c-Myc, MMP-2, and FAK detected by western blotting were downregulated in SLC5A8-transfected HCC cells compared with control-transfected cells, indicating that SLC5A8 has a tumor-suppressive function that acts by interfering with Wnt/β-catenin signaling in HCC.
|
27465549 |
2016 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mitochondrial fission promotes cell migration by Ca<sup>2+</sup> /CaMKII/ERK/FAK pathway in hepatocellular carcinoma.
|
29210177 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly, western blot analysis showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of proteins involved in the fibronectin/integrin/FAK pathway, such as FAK, in both HCC cell lines.
|
28475688 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MACC1 or combination of MACC1/FAK could serve as a novel biomarker in predicting the prognosis of HCC after LT.
|
24516351 |
2014 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The focal adhesion kinase (FAK) gene protein tyrosine kinase 2 is amplified in 16.4% of The Cancer Genome Atlas HCC specimens, and its amplification leads to increased FAK mRNA expression.
|
31069844 |
2019 |
Glioblastoma Multiforme
|
0.550 |
Biomarker
|
disease |
BEFREE |
Also, knockdown- or pharmacological agent-based attenuation of EGFR, FAK or Graf (ARHGAP26)/small GTPase-mediated pathways markedly mitigated the aggressiveness of glioblastoma cells.
|
26377974 |
2015 |
Glioblastoma Multiforme
|
0.550 |
Biomarker
|
disease |
BEFREE |
A recent study showed that a combination of Y15 (a FAK autophosphorylation inhibitor) with temozolomide (TMZ) treatment was effective in glioblastoma (GBM) therapy.
|
31360198 |
2019 |
Glioblastoma Multiforme
|
0.550 |
Biomarker
|
disease |
BEFREE |
Thus, microarray gene expression analysis can be effective in establishing genes affected in response to FAK inhibitor alone and in response to combination of Y15 with temozolomide that is important for glioblastoma therapy.
|
23387973 |
2014 |
Glioblastoma Multiforme
|
0.550 |
AlteredExpression
|
disease |
BEFREE |
In this report, we found that naringin can specifically inhibit the kinase activity of FAK and suppress the FAK<sup>p-Try397</sup>and its downstream pathway in glioblastoma cells.
|
27125297 |
2017 |
Glioblastoma Multiforme
|
0.550 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, the dimeric bicyclic ligand induced cell detachment and inhibited FAK phosphorylation in U-373 MG glioblastoma cells.
|
31556442 |
2019 |
Glioblastoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Also, knockdown- or pharmacological agent-based attenuation of EGFR, FAK or Graf (ARHGAP26)/small GTPase-mediated pathways markedly mitigated the aggressiveness of glioblastoma cells.
|
26377974 |
2015 |